- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: AC430 is an investigational, potent and selective small molecule inhibitor of janus kinase 2 (JAK2) being developed by Ambit (now owned by Daiichi Sankyo) for the treatment of cancer and autoimmune diseases. AC430 is the (R) optical isomer claimed in patent US8703943 , although the (S) isomer and racemate are also discussed in the patent descriptions.
|AC430 is JAK2 inhibitor being developed for the treatment of cancer and autoimmune diseases.|